Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Novo Nordisk
Biotech
Arch-backed obesity biotech launches with $290M
Clinical-stage Metsera has emerged from stealth with $290 million and the bold vision of ushering in the next generation of obesity treatments.
Gabrielle Masson
Apr 18, 2024 7:00am
Novo Nordisk inks $1B buyout to pump up heart failure plans
Mar 25, 2024 7:20am
A look at the R&D landscape in obesity, led by GLP-1s
Mar 19, 2024 8:00am
Another win for Novo in obesity as early oral med beats Wegovy
Mar 7, 2024 9:27am
Real-world data show Abbott’s CGM can help boost GLP-1 gains
Mar 6, 2024 11:16am
Novo Nordisk unveils new US hub as R&D investments soar
Feb 29, 2024 5:00am